Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.

We report the synthesis of a new set of compounds of general structure I (1-20) with structural modifications in the pharmacophoric elements of the previously reported lead UCM-5600. The new derivatives have been evaluated for binding affinity at 5-HT(7) and 5-HT(1A) receptors. The influence of the different structural features in terms of 5-HT(7)/5-HT(1A) receptor affinity and selectivity was analyzed by computational simulations of the complexes between compounds I and beta(2)-based 3-D models of these receptors. Compound 18 (HYD(1) = 1,3-dihydro-2H-indol-2-one; spacer = -(CH(2))(4)-; HYD(2) + HYD(3) = 3,4-dihydroisoquinolin-2(1H)-yl) exhibits high 5-HT(7)R affinity (K(i) = 7 nM) and selectivity over the 5-HT(1A)R (31-fold), and has been characterized as a partial agonist of the human 5-HT(7)R.

[1]  I. Forbes,et al.  Identification of a novel series of selective 5-HT7 receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[2]  M. Erlander,et al.  A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms , 1993, Neuron.

[3]  M. Ferrari,et al.  Sumatriptan in clinical practice , 1996, Neurology.

[4]  Lei Shi,et al.  The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. , 2002, Annual review of pharmacology and toxicology.

[5]  Leonardo Pardo,et al.  The Role of Internal Water Molecules in the Structure and Function of the Rhodopsin Family of G Protein‐Coupled Receptors , 2007, Chembiochem : a European journal of chemical biology.

[6]  J. Sutcliffe,et al.  Mice lacking 5‐HT7 receptors show specific impairments in contextual learning , 2004, The European journal of neuroscience.

[7]  Anne W. Schmidt,et al.  Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides. , 2004, Journal of medicinal chemistry.

[8]  Adrian A Canutescu,et al.  Access the most recent version at doi: 10.1110/ps.03154503 References , 2003 .

[9]  Anne W. Schmidt,et al.  Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site. , 2003, Journal of medicinal chemistry.

[10]  Mateusz Nowak,et al.  Receptor-based pharmacophores for serotonin 5-HT7R antagonists-implications to selectivity. , 2006, Journal of medicinal chemistry.

[11]  P J Lovell,et al.  A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970). , 2000, Journal of medicinal chemistry.

[12]  D. E. Nichols,et al.  Serotonin receptors. , 2008, Chemical reviews.

[13]  R. Lydiard,et al.  An overview of generalized anxiety disorder: disease state--appropriate therapy. , 2000, Clinical therapeutics.

[14]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[15]  L. Pardo,et al.  Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives. , 2003, Journal of medicinal chemistry.

[16]  J. Schuurkes,et al.  Evidence for 5‐HT7 receptors mediating relaxation of human colonic circular smooth muscle , 1999, British journal of pharmacology.

[17]  Rob Leurs,et al.  Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. , 2007, Annual review of pharmacology and toxicology.

[18]  M. Nishiyama,et al.  Synthesis of N-arylpiperazines from aryl halides and piperazine under a palladium tri-tert-butylphosphine catalyst , 1998 .

[19]  J. Terrón,et al.  Is the 5-HT(7) receptor involved in the pathogenesis and prophylactic treatment of migraine? , 2002, European journal of pharmacology.

[20]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[21]  J. Terrón,et al.  Pharmacological evidence for the 5‐HT7 receptor mediating smooth muscle relaxation in canine cerebral arteries , 1999, British journal of pharmacology.

[22]  L. Pardo,et al.  Linking agonist binding to histamine H1 receptor activation , 2005, Nature chemical biology.

[23]  Daniel Hoyer,et al.  Molecular, pharmacological and functional diversity of 5-HT receptors , 2002, Pharmacology Biochemistry and Behavior.

[24]  J. Schwartz,et al.  Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Kołaczkowski,et al.  The impact of spacer structure on 5-HT7 and 5-HT1A receptor affinity in the group of long-chain arylpiperazine ligands. , 2004, Bioorganic & medicinal chemistry letters.

[26]  B. Cooper,et al.  Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents. , 1994, Journal of medicinal chemistry.

[27]  A. Sali,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[28]  P. Lovell.  A Novel, Potent, and Selective 5-HT7 Antagonist: (R)-3-(2-(2- (4-Methylpiperidin-1-yl)-ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970). , 2000 .

[29]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[30]  T. Branchek,et al.  Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation. , 1998, The Journal of pharmacology and experimental therapeutics.

[31]  J. Plassat,et al.  Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. , 1993, Molecular pharmacology.

[32]  J. Lavandera,et al.  First pharmacophoric hypothesis for 5-HT7 antagonism. , 2000, Bioorganic & medicinal chemistry letters.

[33]  C. Kikuchi,et al.  New tetrahydrobenzindoles as potent and selective 5-HT(7) antagonists with increased In vitro metabolic stability. , 2003, Bioorganic & medicinal chemistry letters.

[34]  M. Tonini,et al.  Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. , 2001, Drugs.

[35]  J. Stock,et al.  Circadian Rhythm Phenotype of 5-HT₇ Receptor Knockout Mice: 5-HT and 8-OH-DPAT-Induced Phase Advances of SCN Neuronal Firing , 2005, Journal of biological rhythms.

[36]  T. Schwartz,et al.  Molecular mechanism of 7TM receptor activation--a global toggle switch model. , 2006, Annual review of pharmacology and toxicology.

[37]  S. Henriksen,et al.  5-HT7 Receptor Inhibition and Inactivation Induce Antidepressantlike Behavior and Sleep Pattern , 2005, Biological Psychiatry.

[38]  R. Milne,et al.  Ondansetron , 2012, Drugs.

[39]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[40]  E. Lacivita,et al.  Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents. , 2004, Journal of medicinal chemistry.

[41]  D. Middlemiss,et al.  [3 H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues , 2002, Neuropharmacology.

[42]  J. Sutcliffe,et al.  Functional, molecular and pharmacological advances in 5-HT7 receptor research. , 2004, Trends in pharmacological sciences.

[43]  J. Simard,et al.  Synthesis and structure–activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution , 2005, Journal of enzyme inhibition and medicinal chemistry.

[44]  J. Ramos,et al.  Pd(0) Amination of Benzimidazoles as an Efficient Method towards New (Benzimidazolyl)piperazines with High Affinity for the 5-HT1A Receptor , 2000 .